David Westerman
Overview
Explore the profile of David Westerman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
931
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grigg S, Hing M, Chan K, Juneja S, Westerman D
Br J Haematol
. 2024 Nov;
206(1):365-367.
PMID: 39558798
No abstract available.
2.
Vu M, Degeling K, Westerman D, IJzerman M
J Cancer Policy
. 2024 Aug;
41:100501.
PMID: 39142605
Background: Whole genome sequencing (WGS) has transformative potential for blood cancer management, but reimbursement is hindered by uncertain benefits relative to added costs. This study employed scenario planning and multi-criteria...
3.
Vu M, Degeling K, Ryland G, Hofmann O, Ng A, Westerman D, et al.
J Mol Diagn
. 2024 Jul;
26(8):673-684.
PMID: 39059881
Whole genome and whole transcriptome sequencing (WGTS) can accurately distinguish B-cell acute lymphoblastic leukemia (B-ALL) genomic subtypes. However, whether this is economically viable remains unclear. This study compared the direct...
4.
Handunnetti S, Anderson M, Burbury K, Thompson P, Burke G, Bressel M, et al.
Blood
. 2024 Apr;
144(8):867-872.
PMID: 38662991
In the phase 2 clinical trial (AIM) of venetoclax-ibrutinib, 24 patients with mantle cell lymphoma (MCL; 23 with relapsed/refractory [R/R] disease) received ibrutinib 560 mg and venetoclax 400 mg both...
5.
Harrop S, Nguyen P, Robinson S, Nguyen T, Tiong I, Came N, et al.
Br J Haematol
. 2024 Mar;
204(6):2492-2495.
PMID: 38544472
No abstract available.
6.
Gould C, McBean M, Thompson E, Lickiss J, Tiong I, Westerman D, et al.
Pathology
. 2024 Feb;
56(4):540-547.
PMID: 38413254
External quality assessment programs (EQAP) for molecular haematology generally only assess the analytical phase of laboratory testing or provide limited evaluation of post-analytical components. We incorporated comprehensive post-analytical evaluation into...
7.
Minson A, Hamad N, Cheah C, Tam C, Blombery P, Westerman D, et al.
Blood
. 2023 Oct;
143(8):673-684.
PMID: 37883795
CD19-directed chimeric antigen receptor T cells (CAR-T) achieve high response rates in patients with relapsed/refractory mantle cell lymphoma (MCL). However, their use is associated with significant toxicity, relapse concern, and...
8.
Vu M, Degeling K, Thompson E, Blombery P, Westerman D, IJzerman M
Appl Health Econ Health Policy
. 2023 Aug;
22(1):107-122.
PMID: 37608228
Background: Clinical indications for ibrutinib reimbursement in Australia should consider the inclusion of patients with chronic lymphocytic leukemia (CLL) harboring prognostically unfavorable TP53/IGHV genomic aberrations. This study assessed the cost...
9.
Wu S, Blombery P, Westerman D, Tam C
Curr Treat Options Oncol
. 2023 May;
24(8):929-947.
PMID: 37249800
Mantle cell lymphoma (MCL) treatment advances have significantly improved disease-free remission, with greater focus in clinical trials being placed on measurable residual disease (MRD) as a marker of subclinical disease...
10.
Nedumannil R, Ritchie D, Bajel A, Ng A, Harrison S, Westerman D
Eur J Haematol
. 2022 Nov;
110(2):168-176.
PMID: 36321745
Multi-parametric flow cytometry (MFC) has a well-established role in measurable residual disease (MRD) monitoring in patients with B-lymphoblastic leukemia (B-ALL). However, the optimal time-point (TP) for early MRD testing and...